Evolutionary Genomics Inc
Evolutionary Genomics, Inc., together with its subsidiaries, engages in the research and identification of positively selected genes in humans, animals, and commercial crops. The company develops Adapted Traits Platform, a technology platform to identify genes for enhancing crop plant traits, such as yield, sugar content, biomass, drought tolerance, and pest/disease resistance. It serves governme… Read more
Evolutionary Genomics Inc (FNAM) - Total Assets
Latest total assets as of December 2022: $2.35 Million USD
Based on the latest financial reports, Evolutionary Genomics Inc (FNAM) holds total assets worth $2.35 Million USD as of December 2022.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Evolutionary Genomics Inc - Total Assets Trend (2009–2022)
This chart illustrates how Evolutionary Genomics Inc’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Evolutionary Genomics Inc - Asset Composition Analysis
Current Asset Composition (December 2022)
Evolutionary Genomics Inc's total assets of $2.35 Million consist of 29.7% current assets and 70.3% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 24.5% |
| Accounts Receivable | $78.00K | 3.3% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $3.96K | 0.2% |
| Intangible Assets | $1.65 Million | 70.1% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2009–2022)
This chart illustrates how Evolutionary Genomics Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Evolutionary Genomics Inc's current assets represent 29.7% of total assets in 2022, a decrease from 100.0% in 2009.
- Cash Position: Cash and equivalents constituted 24.5% of total assets in 2022, down from 98.2% in 2009.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 70.0% of total assets, an increase from 0.0% in 2009.
- Asset Diversification: The largest asset category is intangible assets at 70.1% of total assets.
Evolutionary Genomics Inc Competitors by Total Assets
Key competitors of Evolutionary Genomics Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
MedPacto Inc
KQ:235980
|
Korea | ₩51.58 Billion |
|
2H0
F:2H0
|
Germany | €15.27 Million |
|
Shenzhen CAU Technology Co Ltd
SHE:000004
|
China | CN¥260.55 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.58 Billion |
|
Nanhua Bio Medicine Co Ltd
SHE:000504
|
China | CN¥841.96 Million |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
|
China | CN¥509.14 Million |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
|
Hualan Biological EngineeringInc
SHE:002007
|
China | CN¥16.27 Billion |
Evolutionary Genomics Inc - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - Evolutionary Genomics Inc generates 0.00x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Evolutionary Genomics Inc is currently not profitable relative to its asset base.
Evolutionary Genomics Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 3.92 | 13.56 | 90.99 |
| Quick Ratio | 3.92 | 13.56 | 90.99 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $520.67K | $ 236.94K | $ 927.22K |
Evolutionary Genomics Inc - Advanced Valuation Insights
This section examines the relationship between Evolutionary Genomics Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | - |
| Latest Market Cap to Assets Ratio | 0.00 |
| Asset Growth Rate (YoY) | -19.7% |
| Total Assets | $2.35 Million |
| Market Capitalization | $1.33K USD |
Valuation Analysis
Below Book Valuation: The market values Evolutionary Genomics Inc's assets below their book value (0.00 x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Evolutionary Genomics Inc's assets decreased by 19.7% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Evolutionary Genomics Inc (2009–2022)
The table below shows the annual total assets of Evolutionary Genomics Inc from 2009 to 2022.
| Year | Total Assets | Change |
|---|---|---|
| 2022-12-31 | $2.35 Million | -19.73% |
| 2021-12-31 | $2.93 Million | -26.56% |
| 2020-12-31 | $3.99 Million | -5.89% |
| 2019-12-31 | $4.24 Million | -3.33% |
| 2018-12-31 | $4.39 Million | -18.72% |
| 2017-12-31 | $5.40 Million | -15.67% |
| 2016-12-31 | $6.40 Million | +101.92% |
| 2015-12-31 | $3.17 Million | +133.43% |
| 2014-12-31 | $1.36 Million | +136968.11% |
| 2013-12-31 | $991.00 | +52.23% |
| 2012-12-31 | $651.00 | +78.85% |
| 2011-12-31 | $364.00 | -0.27% |
| 2010-12-31 | $365.00 | -98.07% |
| 2009-12-31 | $18.95K | -- |